Literature DB >> 2338117

Evolution of atenolol kinetics when hypothyroidism is corrected.

H Levesque1, M O Richard, J Fresel, A Gancel, N Moore, H Courtois.   

Abstract

A single oral dose of atenolol 100 mg was given to 7 hypothyroid patients (4 F, 3 M), before and after correction of hypothyroidism, mean delay 3.5 months (2 to 6.5 months). There was no change in the elimination parameters of atenolol, but the maximal plasma atenolol concentration was increased (1.66 to 7.37 mg.l-1) as was the AUC (14.9 to 52.1 mg.l-1.h) when the hypothyroidism had been treated. Only one patient differed: he had had a supra-selective vagotomy, and had similar curves before and after treatment of the hypothyroidism, both being similar to the plasma concentration curves found in the other patients after correction of the hypothyroidism. The results suggest an increase in the bioavailability of atenolol when hypothyroidism is corrected. The findings in the patient with vagotomy suggest that the decreased bioavailability during hypothyroidism might be related to changes in intestinal pH. Further studies are needed of the impact of hypothyroidism on gastric and pancreatic or biliary function and its consequences for drug absorption, and drug pharmacokinetics.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2338117     DOI: 10.1007/bf00265982

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  Studies of the effect of thyroid dysfunction on the elimination of beta-adrenoreceptor blocking drugs.

Authors:  J M Bell; C J Russell; J K Nelson; J G Kelly; D G McDevitt
Journal:  Br J Clin Pharmacol       Date:  1977-02       Impact factor: 4.335

2.  [Spectrofluorimetric estimation in biological fluids of a new beta-blockader: atenolol. Application to its pharmacokinetic study (author's transl)].

Authors:  B Flouvat; M Bazin; M Lucsko; A Roux; J Guedon
Journal:  Ann Biol Clin (Paris)       Date:  1978       Impact factor: 0.459

Review 3.  Thyroid hormones and the gut.

Authors:  W R Middleton
Journal:  Gut       Date:  1971-02       Impact factor: 23.059

Review 4.  Influence of thyroid dysfunction on drug pharmacokinetics.

Authors:  G M Shenfield
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of beta-adrenoceptor blocking drugs in thyroid disease.

Authors:  J Feely
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

Review 6.  Drugs, diseases and altered gastric emptying.

Authors:  W S Nimmo
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

7.  Altered plasma protein binding of drugs in thyroid disease.

Authors:  J Feely; I H Stevenson; J Crooks
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

8.  Thyrotropin-releasing hormone injected intracerebroventricularly in the rat stimulates exocrine pancreatic secretion via the vagus nerve.

Authors:  Y Kato; T Kanno
Journal:  Regul Pept       Date:  1983-12

9.  Effects of thyrotropin-releasing hormone on pancreatic exocrine secretion in the dog.

Authors:  F Yamagishi; F Iijima; K Iwatsuki; I Komiya; T Yamada; S Chiba
Journal:  Arch Int Pharmacodyn Ther       Date:  1985-03

10.  Thyrotropin-releasing hormone inhibits pancreatic enzyme secretion in humans.

Authors:  L Gullo; G Labò
Journal:  Gastroenterology       Date:  1981-04       Impact factor: 22.682

  10 in total
  1 in total

Review 1.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.